Skip to main content
AYTU BIOPHARMA, INC logo

AYTU BIOPHARMA, INC — Investor Relations & Filings

Ticker · AYTU ISIN · US0547548745 US Manufacturing
Open in API
Filings indexed 890 across all filing types
Latest filing 2025-06-26 Major Shareholding Noti…
Country US United States of America
Listing US AYTU

About AYTU BIOPHARMA, INC

https://aytubio.com/

Aytu BioPharma, Inc. is a specialty pharmaceutical company focused on developing and commercializing novel therapeutics. The company concentrates on advancing innovative medicines for complex central nervous system (CNS) diseases, with a particular emphasis on treatments for Attention-Deficit/Hyperactivity Disorder (ADHD) and Major Depressive Disorder (MDD). Its business model involves identifying, acquiring, and commercializing new products to improve the quality of life for patients with unmet medical needs.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2025
Major Shareholding Notification
2025-06-26 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-06-26 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes an amendment to a loan and security agreement, including details about loan maturity extension, increased principal amount, and changes to revolving credit facilities. It also references a press release attached as an exhibit. There are no financial statements or comprehensive financial data presented, only a description of a financing agreement amendment. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document length is 5867 characters, sufficient to contain substantive information rather than a brief announcement. Therefore, the classification is CAP with high confidence.
2025-06-23 English
FORM 8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated June 17, 2025, by Aytu BioPharma, Inc. The key content is an announcement that the company has posted an updated investor presentation on its website and attached it as Exhibit 99.1. The text explicitly states that the presentation is for upcoming investor meetings and includes product opportunity information. The document does not contain detailed financial statements or analysis but rather serves to disclose the availability of the investor presentation. The document length is 3755 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this filing is best classified as an Investor Presentation (IP).
2025-06-17 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-06-13 English
FORM 4
Director's Dealing
2025-06-10 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.